An Open-Label, Relative Bioavailability Study Evaluating the Safety, Tolerability, and Pharmacokinetics of Ropinirole Implants in Patients With Parkinson's Disease Switched From Oral Immediate-Release Ropinirole While on L-Dopa

Trial Profile

An Open-Label, Relative Bioavailability Study Evaluating the Safety, Tolerability, and Pharmacokinetics of Ropinirole Implants in Patients With Parkinson's Disease Switched From Oral Immediate-Release Ropinirole While on L-Dopa

Not yet recruiting
Phase of Trial: Phase I/II

Latest Information Update: 17 Aug 2017

At a glance

  • Drugs Ropinirole (Primary) ; Ropinirole (Primary)
  • Indications Parkinson's disease
  • Focus Pharmacokinetics; Proof of concept
  • Sponsors Titan Pharmaceuticals
  • Most Recent Events

    • 11 Aug 2017 Status changed from planning to not yet recruiting.
    • 17 May 2017 Planned initiation date changed from 1 Jun 2016 to 1 Sep 2017.
    • 10 May 2017 According to a Titan Pharmaceuticals media release, the company expects to initiate this study in the third quarter of 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top